Episode 6: Recent Clinical Advances in Reducing Risk for Dyslipidemia
Medscape,
This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape InDiscussion.
This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape InDiscussion.
Here are what the editors at HealthDay consider to be the most important developments in Neurology for May 2020.
Here are what the editors at HealthDay consider to be the most important developments in Psychiatry for May 2020.
Here are what the editors at HealthDay consider to be the most important developments in Cardiology for May 2020.
For patients with atherosclerotic CVD and LDL-C ≥70 mg/dL or non-high-density cholesterol ≥100 mg/dL despite statin therapy…
L'aggiunta dell'inibitore PCSK9 evolocumab alla terapia con statina in pazienti con malattia cardiovascolare (CVD…
“Within the context of who the trial was performed in, it seems to be pretty safe over about a 3-year period,” one expert says.
HealthDay News – For patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) ≥70mg/d…
Heart disease patients taking evolocumab in addition to a statin to achieve extremely low levels of cholesterol do not show…
(HealthDay News) -- For patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) ≥70…
Cardiology > Prevention Even very low LDL not linked to worse cognitive outcomes in FOURIER by Staff Writer, MedPage Today May 4…
Credit: CC0 Public Domain Heart disease patients taking evolocumab in addition to a statin to achieve extremely low levels of…
-- For patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL or non-high…
Heart disease patients taking evolocumab in addition to a statin to achieve extremely low levels of cholesterol do not show…